Uniqure NV (QURE) CEO Matthew C. Kapusta Sells 39,169 Shares of Stock
Uniqure NV (NASDAQ:QURE) CEO Matthew C. Kapusta sold 39,169 shares of the business’s stock in a transaction on Thursday, March 15th. The shares were sold at an average price of $21.72, for a total value of $850,750.68. Following the completion of the sale, the chief executive officer now owns 439,764 shares in the company, valued at approximately $9,551,674.08. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.
Matthew C. Kapusta also recently made the following trade(s):
- On Thursday, January 4th, Matthew C. Kapusta sold 21,690 shares of Uniqure stock. The stock was sold at an average price of $19.87, for a total value of $430,980.30.
Shares of Uniqure NV (NASDAQ:QURE) opened at $20.78 on Tuesday. The company has a current ratio of 8.46, a quick ratio of 8.46 and a debt-to-equity ratio of 0.22. Uniqure NV has a 1-year low of $4.72 and a 1-year high of $27.19. The firm has a market capitalization of $684.06, a PE ratio of -7.07 and a beta of 0.09.
Several large investors have recently added to or reduced their stakes in QURE. SG Americas Securities LLC acquired a new position in shares of Uniqure during the 4th quarter worth about $119,000. Ellington Management Group LLC acquired a new position in shares of Uniqure during the 4th quarter worth about $237,000. Goldman Sachs Group Inc. acquired a new position in shares of Uniqure during the 4th quarter worth about $373,000. Virtus Fund Advisers LLC acquired a new position in shares of Uniqure during the 4th quarter worth about $389,000. Finally, OxFORD Asset Management LLP acquired a new position in shares of Uniqure during the 3rd quarter worth about $399,000. 43.98% of the stock is owned by institutional investors and hedge funds.
uniQure N.V., a biopharmaceutical company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. The company's principle programs include AMT-060, a gene therapy that has completed Phase I/II clinical trial for the treatment of hemophilia B; S100A1, a preclinical product candidate for the treatment of congestive heart failure; and AMT-130 for the treatment of huntington's disease.
Receive News & Ratings for Uniqure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uniqure and related companies with MarketBeat.com's FREE daily email newsletter.